Company news

UroGen Pharma Ltd. news in 2024

UroGen Pharma Ltd.'s news releases, calls and decks from 2024, newest first.

View company

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

December 4, 2024

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

December 4, 2024

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

December 1, 2024

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

November 25, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

November 5, 2024

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

November 4, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

October 29, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

October 27, 2024

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

October 14, 2024

UroGen Appoints Chris Degnan as Chief Financial Officer

October 8, 2024

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

October 1, 2024

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

September 15, 2024

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 13, 2024

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

August 12, 2024

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

August 4, 2024

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

June 16, 2024

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

June 16, 2024

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

June 12, 2024

UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

June 5, 2024

UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

June 4, 2024

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

June 2, 2024

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 21, 2024

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

May 12, 2024

UroGen Pharma to Participate at Upcoming Investor Conferences

May 6, 2024

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

May 4, 2024

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

May 3, 2024

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

May 3, 2024

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

May 2, 2024

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

April 16, 2024

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

April 14, 2024

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

April 2, 2024

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

March 13, 2024

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

March 3, 2024

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference

February 25, 2024

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

January 23, 2024

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

January 16, 2024

UroGen Pharma to Participate in the B. Riley Healthcare Conference

January 10, 2024

Calls in 2024

Decks in 2024